InMed Pharmaceuticals (INM) Depreciation and Depletion (2019 - 2025)

InMed Pharmaceuticals has reported Depreciation and Depletion for 7 years, with the latest figure at $12206.0 in Q2 2025.

• For the quarter ending Q2 2025, Depreciation and Depletion rose 124.37% year-over-year to $12206.0; the trailing twelve-month figure through Jun 2025 stood at $50204.0 (up 5.16% YoY), and the FY2025 full-year result was $50204.0, up 5.16% from the prior year.
• Depreciation and Depletion for Q2 2025 stood at $12206.0, roughly flat from $12203.0 in the prior quarter.
• The five-year high for Depreciation and Depletion was $14242.0 in Q4 2023, with the low at $3633.0 in Q1 2021.
• Historically, Depreciation and Depletion has averaged $9859.8 across 5 years, with a median of $10586.0 in 2023.
• Annual changes were most pronounced in 2021 — Depreciation and Depletion plunged 86.48% — and 2025, when it soared 124.37%.
• InMed Pharmaceuticals' Depreciation and Depletion stood at $6246.0 in 2021, then advanced by 28.98% to $8056.0 in 2022, then jumped by 76.79% to $14242.0 in 2023, then retreated by 14.27% to $12209.0 in 2024, then dropped by 0.02% to $12206.0 in 2025.
• The last three Depreciation and Depletion figures came in at $12206.0 (Q2 2025), $12203.0 (Q1 2025), and $12209.0 (Q4 2024), per Business Quant data.